Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Sponsor: Guangdong Provincial People's Hospital
Summary
Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in EGFR-mutant stage IIA-IIIB NSCLC followed by surgery, adjuvant treatment was upon investigators' decisions.
Official title: Neoadjuvant Almonertinib Followed by Adebrelimab-based Chemo-immunotherapy in II-IIIB EGFR-mutant Non-small Cell Lung Cancer, a Single Arm, Phase II Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2024-04
Completion Date
2027-09
Last Updated
2024-04-17
Healthy Volunteers
No
Interventions
almonertinib
110mg qd
Carboplatin
AUC 5, d1 every 3 weeks
Nab paclitaxel
135 mg/m2, d1,d8 every 3 weeks
Locations (1)
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences
Guangzhou, Guangdong, China